Conditions: Alzheimer's Disease Mild Cognitive Impairment
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 16
Healthy volunteers: no

Brief summary:
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD). Subjects who meet entry criteria will undergo 11C-PiB (Carbon-11-labeled Pittsburgh Compound B) positron emission tomography (PET) at baseline and after 45 days of dosing with VX-745. Cognitive testing will also be conducted at baseline and day 45.

Detailed description:

Arms:
arm 1: Active Group 1: VX-745 40 mg twice daily arm 2: Active Group 2: VX-745 125 mg twice daily

Interventions: intervention 1: VX-745
Intervention descriptions: intervention 1: Orally-Active Selective P45 MAP Kinase inhibitor

Protocol document: